Recent advances in immunohistochemistry in gynaecological pathology

Histopathology

Volumn 40, Issue 4, 2002, Pages 309-326

  McCluggage, W G ^a  

^a ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

Author keywords

Cervix; Differential diagnosis; Endometrium; Immunohistochemistry; Ovary; Uterus; Vagina; Vulva

Indexed keywords

ANTIBODY; BIOLOGICAL MARKER; CALDESMON; CARCINOEMBRYONIC ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYTOKERATIN; CYTOKERATIN 20; CYTOKERATIN 7; INHIBIN; PROTEIN P57; VIMENTIN;

ADENOCARCINOMA; ADENOMA; ADNEXA DISEASE; CELL STRUCTURE; ENDOMETRIUM CARCINOMA; GYNECOLOGIC CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; MESENCHYMOMA; MESOTHELIOMA; METASTASIS; OVARY ADENOCARCINOMA; OVARY CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SMALL CELL SARCOMA; TROPHOBLASTIC DISEASE; UTERINE CERVIX CARCINOMA; UTERUS CARCINOMA; VAGINA CARCINOMA; VULVA CARCINOMA;

FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; OVARIAN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; UTERINE NEOPLASMS; VAGINAL NEOPLASMS; VULVAR NEOPLASMS;

EID: 0036268240     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.2002.01384.x     Document Type: Review

References (167)

1. Recent advances in immunohistochemistry in the diagnosis of ovarian neoplasms
2. The value of inhibin staining in gynecological pathology
3. The value of immunocytochemistry in distinguishing between clear cell carcinoma of the kidney and ovary
4. Monoclonal antibody to a proximal nephrogenic renal antigen: Immunohistochemical analysis of formalin-fixed, paraffin-embedded human renal cell carcinomas
5. Diagnosing primary and metastatic renal cell carcinoma: The use of the monoclonal antibody "renal cell carcinoma marker"
6. Metastatic intestinal carcinomas simulating primary ovarian clear cell carcinoma and-secretory endometrioid carcinoma: A clinicopathologic and-immunohistochemical study of five cases
7. Keratins 7 and 20 as diagnostic markers of carcinomas metastatic to the ovary
8. Tracing the origin of adenocarcinomas with unknown primary using immunohistochemistry. Differential diagnosis between colonic and ovarian carcinomas as primary sites
9. Cytokeratins 7 and 20 and carcinoembryonic antigen in ovarian and colonic carcinoma
10. Cytokeratin immunostaining in differentiating primary ovarian carcinoma from metastatic colonic adenocarcinoma
11. Immunohistochemical study of cytokeratin 7 for the differentiated diagnosis of adenocarcinoma in the ovary
12. Mucinous tumors of the vermiform appendix and ovary, and pseudomyxoma peritonei. Histogenetic implications of cytokeratin 7 expression
13. Immunohistochemical evidence supporting the appendiceal origin of pseudomyxoma peritonei in women
14. Metastases from carcinomas of the pancreas simulating primary mucinous tumors of the ovary: A report of seven cases
15. Ovarian metastases from carcinoma of the gallbladder and extrahepatic bile ducts simulating primary tumors of the ovary: A report of six cases
16. Differential expression of MUC2 and MUC5AC mucin genes in primary ovarian and metastatic colonic carcinoma
17. Malignant mesotheliomas presenting as ovarian masses. A report of nine cases, including two primary ovarian mesotheliomas
18. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas
19. A comparative immunohistochemical study of peritoneal and ovarian serous tumors and mesotheliomas
20. Monoclonal antibody SMO47 as an immunohistochemical marker of ovarian adenocarcinoma
21. Immunohistochemical distribution of tumor-associated antigen CA6 in gynecological neoplasms as detected by monoclonal antibody DS6
22. Immunohistochemical detection of the Wilms' tumour gene (WT1) in epithelial ovarian tumors
23. Clear cell carcinoma has an expression pattern of cell cycle regulatory molecules that is unique among ovarian adenocarcinomas
24. Brenner tumors but not transitional cell carcinomas of the ovary show urothelial differentiation: Immunohistochemical staining of urothelial markers, including cytokeratins and uroplakins
25. Transitional cell carcinomas of the ovary and bladder are immunophenotypically different
26. Transitional cell neoplasms of the ovary and urinary bladder: A comparative immunohistochemical analysis
27. Immunohistochemical analysis of uroplakins, urothelial specific proteins, in ovarian Brenner tumors, normal tissues, and benign and neoplastic lesions of the female genital tract
28. Immunophenotype of transitional metaplasia of the uterine cervix
29. Ovarian sex cord-stromal tumors. Problems in differential diagnosis
30. Immunohistochemical staining of ovarian granulosa cell tumors with monoclonal antibody against inhibin
31. α and β subunits of inhibin/activin as sex cord-stromal differentiation markers
32. Diagnostic value of inhibin immunoreactivity in ovarian gonadal stromal tumours and their histological mimics
33. Value of inhibin in the identification of granulosa cell tumors of the ovary
34. Inhibin immunohistochemistry applied to ovarian neoplasms: A novel, effective diagnostic tool
35. Making sense of inhibin in ovarian tumours
36. Inhibin expression in ovarian tumors and tumor-like lesions: An immunohistochemical study
37. Production of inhibin A and inhibin B in human ovarian sex cord stromal tumors
38. Mullerian inhibiting substance, alpha-inhibin, and CD99 expression in sex cord-stromal tumors and endometrioid ovarian carcinomas resembling sex cord-stromal tumors
39. Inhibin and epithelial membrane antigen immunohistochemistry assist in the diagnosis of sex cord-stromal tumors and provide clues to the histogenesis of hypercalcaemic small cell carcinomas
40. Use of monoclonal antibody against human inhibin as a marker for sex cord-stromal tumors of the ovary
41. Monoclonal antibodies against inhibin represent key markers of adult granulosa cell tumors of the ovary even in their metastases
42. The diagnostic utility of inhibin staining in ovarian neoplasms
43. Ovarian endometrioid carcinomas simulating sex cord-stromal tumors: A study using inhibin and cytokeratin 7
44. Immunohistochemical staining for calretinin is useful in the diagnosis of ovarian sex cord-stromal tumours
45. Calretinin: A novel immunocytochemical marker for mesothelioma
46. Expression of calretinin in human ovary, testis and ovarian sex cord-stromal tumors
47. Value of A103 (melan-A) immunostaining in the differential diagnosis of ovarian sex cord tumors
48. Immunoreactivity for A103, an antibody to melan-A (Mart-1) in adrenocortical and other steroid tumors
49. Immunohistochemical staining of ovarian granulosa cell tumours with MIC2 antibody
50. CD99, keratin and vimentin staining of sex cord-stromal tumors, normal ovary and testis
51. Mullerian inhibiting substance as a marker for sex-cord tumor
52. Immunoreactive inhibin, mullerian inhibiting substance and activin as biochemical markers for juvenile granulosa cell tumors
53. Relaxin-like factor (RLF): A new specific marker for Leydig cells in the ovary
54. Adenocarcinomas of various sites may exhibit immunoreactivity with anti-inhibin antibodies
55. Ovarian endometrioid carcinomas resembling sex cord-stromal tumors: An immunohistochemical study
56. Intermediate filamentous proteins in adult granulosa cell tumors
57. Co-expression of cytokeratin and vimentin flaments in mesothelial, granulosa and rete ovarii cells of the human ovary
58. Immunohistochemical phenotype of ovarian granulosa cell tumors: Absence of epithelial membrane antigen has diagnostic value
59. Immunohistochemical analysis of gynecologic tumors
60. Immunohistochemical study of 3 beta-hydroxysteroid dehydrogenase in sex cord-stromal tumors of the ovary
61. Sex steroid biosynthesis enzymes in ovarian sex cord-stromal tumors
62. Distribution of alpha glutathione S-transferase in ovarian neoplasms: An immunohistochemical study
63. Sclerosing stromal tumors, thecomas and fibromas of the ovary: An immunohistochemical profile
64. Expression of estrogen receptor beta in ovarian granulosa cell tumors
65. Uterine tumors resembling ovarian sex cord tumors: A clinicopathologic analysis of fourteen cases
66. Uterine tumors resembling ovarian sex-cord tumors have an immunophenotype consistent with true sex-cord differentiation
67. Inhibin and CD 99 (MIC2) expression in uterine stromal neoplasms with sex cord-like elements
68. Uterine tumours resembling ovarian sex cord tumours: Immunohistochemical evidence for true sex cord differentiation
69. Wolffian adnexal tumor, so-called female adnexal tumor of probable Wolffian origin (FATWO): Immunohistochemical evidence in support of a Wolffian origin
70. The site of inhibin production in ovarian neoplasms
71. Mucinous cystic tumors of the pancreas: Clinicopathological features, prognosis and relationship to other tumors
72. Immunocytochemical staining of ovarian cyst aspirates with monoclonal antibody against inhibin
73. Desmoplastic small round cell tumor II. An ultrastructural and immunohistochemical study with emphasis on new immunohistochemical markers
74. Immunohistochemical detection of the Wilms' tumour gene WT1 in desmoplastic small round cell tumour
75. Peripheral primitive neuroectodermal tumor of the ovary confirmed by CD99 immunostaining, karyotypic analysis, and RT-PCR for EWS/FL-1 chimeric in mRNA
76. Parathyroid hormone-related protein expression in small cell carcinomas of the ovary and cervix correlates with the hypercalcaemic type
77. Female adnexal tumours of probable Wolffian origin: An immunohistochemical study comparing tumours, mesonephric remnants and-paramesonephric derivatives
78. Mesonephric adenocarcinoma of the uterine corpus: CD10 expression as evidence of mesonephric differentiation
79. Myxoid and fibrous endometrial stromal tumors of the uterus. A report of 10 cases
80. Cellular benign mesenchymal tumors of the uterus: A comparative morphologic and immunohistochemical analysis of 33 highly cellular leiomyomas and seven endometrial stromal nodules, two frequently confused tumors
81. An immunohistochemical study of normal endometrial stroma and endometrial stromal neoplasms: Evidence for smooth muscle differentiation
82. Immunohistochemistry as a diagnostic aid in the interpretation of unusual mesenchymal tumors of the uterus
83. Immunohistochemistry of endometrial stromal sarcoma
84. CD10 is a sensitive and diagnostically useful immunohistochemical marker of normal endometrial stroma and of endometrial stromal neoplasms
85. Utility of CD10 in distinguishing between endometrial stromal sarcoma and uterine smooth muscle tumors: An immunohistochemical comparison of 34 cases
86. h-Caldesmon expression effectively distinguishes endometrial stromal tumors from uterine smooth muscle tumors
87. h-Caldesmon, a novel smooth muscle-specific antibody, distinguishes between cellular leiomyoma and endometrial stromal sarcoma
88. Immunohistochemical distinction of endometrial stromal sarcoma and cellular leiomyoma
89. CD10 is a marker for normal and neoplastic endometrial stromal cells
90. Mixed endometrial stromal and smooth muscle tumors of the uterus: A clinicopathologic study of 15 cases
91. Smooth muscle differentiation in genital tract disorders
92. CD10 is useful in demonstrating endometrial stroma at ectopic sites and in confirming a diagnosis of endometriosis
93. Perivascular epithelioid cell tumor (PEComa) of the uterus: A subset of HMB-45-positive epithelioid mesenchymal neoplasms with an uncertain relationship to pure smooth muscle tumors
94. Minimal uterine serous carcinoma: Diagnosis and-clinicopathologic correlation
95. Direct sequencing of the p53 gene shows absence of mutations in endometrioid endometrial adenocarcinomas expressing p53 protein
96. Endometrial intraepithelial carcinoma: Distinctive lesion specifically associated with tumors displaying serous differentiation
97. Endometrial carcinoma in situ in postmenopausal women
98. Serous carcinoma in endometrial polyps
99. Uterine serous carcinoma and endometrial intraepithelial carcinoma arising in endometrial polyp: Report of five cases including two associated with tamoxifen therapy
100. The immunohistochemical discrimination of endometrioid adenocarcinomas
101. Endocervical and endometrial adenocarcinoma: An immunoperoxidase and-histochemical study
102. Intermediate flaments in endometrial and endocervical carcinomas. The diagnostic utility of vimentin patterns
103. Distinction between endometrial and endocervical adenocarcinomas: An immunohistochemical study
104. A panel of immunohistochemical stains, including carcinoembryonic antigen, vimentin and estrogen receptor, aids the distinction between primary endometrial and endocervical adenocarcinomas
105. Hormone receptor immunohistochemistry (IHC) and HPV in situ hybridization (ISH) are useful for distinguishing between primary endocervical and endometrial adenocarcinomas
106. Plasma cells in chronic endometritis are easily identified when stained with syndecan-1
107. Anti-CD38 and VS38 antibodies for detection of plasma cells in the diagnosis of chronic endometritis
108. Inter and intraobserver variation in the histopathological reporting of cervical squamous intraepithelial lesions using a modified Bethesda grading system
109. Interobserver variation in the reporting of cervical colposcopic biopsies. Comparison of grading systems
110. Monoclonal antibody MIB1 in the assessment of cervical squamous intraepithelial lesions
111. Immunohistochemical detection of metallothionein and-MIB1 in uterine cervical squamous lesions
112. Proliferating cell nuclear antigen (cyclin) expression in normal and-abnormal cervical squamous epithelia
113. Expression of the proliferating cell nuclear antigen in cervical neoplasia
114. The proliferative activity in dysplasia and carcinoma in situ of the uterine cervix analysed by proliferating cell nuclear antigen immunostaining and silver-binding argyrophilic nucleolar organiser region staining
115. MIB1, a promising marker for the classification of cervical intraepithelial neoplasia
116. Assessment of Ki-67 antigen immunostaining in squamous intraepithelial lesions of the uterine cervix: Correlation with histological grade and-human papilloma virus type
117. Proliferation in the normal cervix and in preinvasive cervical lesions
118. Proliferation in the normal cervix and in preinvasive cervical lesions
119. Utility of proliferation-associated marker MIB1 in evaluating lesions of the uterine cervix
120. MIB1 expression is useful in distinguishing dysplasia from atrophy in elderly women
121. Diagnostic accuracy of cervical low-grade squamous intraepithelial lesions is improved with MIB1 immunostaining
122. Utility of MIB1 in evaluating cauterised cervical cone biopsy margins
123. Ki-67, cyclin E and p16 (INK4) are complimentary surrogate biomarkers for human papilloma virus-related cervical neoplasia
124. Over expression of p16 (INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri
125. P16 ink4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia
126. Immunocytochemical analysis of p16 protein in cervical cancer and cervical intraepithelial neoplasia
127. Monoclonal antibodies Ki-67 and MIB1 in the distinction of tuboendometrial metaplasia from endocervical adenocarcinoma and adenocarcinoma in situ in formalin fixed material
128. Quantitative image analysis of MIB1 reactivity in inflammatory, hyperplastic and neoplastic endocervical lesions
129. Proliferative activity of benign and-neoplastic endocervical epithelium and correlation with HPV DNA detection
130. Immunohistochemical staining for Ki-67 antigen, carcinoembryonic antigen, and p53 in the differential diagnosis of glandular lesions of the cervix
131. Endocervical adenocarcinoma in situ of tubal type and its relationship to atypical tubal metaplasia
132. Immunohistochemical detection of p53 and bcl2 proteins, in neoplastic and nonneoplastic endocervical glandular lesions
133. bcl-2 and p21 immunostaining of cervical tubo-endometrial metaplasia
134. Endocervical tubal metaplasia and adenocarcinoma in situ: Role of immunohistochemistry for carcinoembryonic antigen and-vimentin in differential diagnosis
135. Adenoma malignum/minimal deviation adenocarcinoma of the uterine cervix. A clinicopathological and immunohistochemical analysis of 26 cases
136. Minimal deviation endocervical adenocarcinoma: Clinical and histologic features, immunohistochemical staining for carcinoembryonic antigen and differentiation from confusing benign lesions
137. CD44 is a marker of endocervical neoplasia
138. A new diagnostic method for adenoma malignum and related lesions: Latex aglutination test with a new monoclonal antibody, HIK 1083
139. Immunohistochemical expression of gastric mucin and p53 in minimal deviation adenocarcinoma of the uterine cervix
140. Adenoma malignum - Report of a case with cytologic and-colposcopic findings and immunohistochemical staining with antimucin monoclonal antibody HIK-1083
141. Utility of the monoclonal antibody HIK1083 in the diagnosis of adenoma malignum of the uterine cervix
142. Lobular endocervical glandular hyperplasia is a metaplastic process with a pyloric gland phenotype
143. Localisation of the cellular expression of inhibin in trophoblastic tissue
144. Immunohistochemical expression analysis of inhibin-alpha and beta subunits in partial and complete moles, trophoblastic tumors and endometrial decidua
145. Placental site nodule and characterisation of distinctive types of intermediate trophoblast
146. Immunohistochemical localisation of inhibin-alpha in the placenta and gestational trophoblastic lesions
147. Detection of the alpha-subunit of inhibin in trophoblastic neoplasia
148. Epithelioid trophoblastic tumor - A neoplasm distinct from choriocarcinoma and placental site trophoblastic tumor simulating carcinoma
149. Frequent expression of beta-human chorionic gonadotropin (beta-HCG) in squamous cell carcinoma of the cervix
150. The pathology of intermediate trophoblastic tumors and tumor-like lesions
151. Ki-67 labelling index in the differential diagnosis of exaggerated placental site, placental site trophoblastic tumor and choriocarcinoma. A double immunohistochemical staining technique using Ki-67 and mel CAM antibodies
152. Discrimination of complete hydatidiform mole from its mimics by immunohistochemistry of the paternally imprinted gene product p57 (KIP2)
153. Inhibin expression in normal and pre-eclamptic placental tissue
154. Vulvovaginal soft tissue tumours: Update and review
155. Aggressive angiomyxoma of pelvic parts exhibits oestrogen and-progesterone receptor postivity
156. So-called fibroepithelial polyps of the vagina exhibiting an unusual but uniform antigen profile characterised by expression of desmin and steroid hormone receptors but no muscle-specific actin or macrophages markers
157. Angiomyofibroblastoma of the vulva and vagina
158. Chromosomal translocation t(8;12) induces aberrant HMGIC expression in aggressive angiomyxoma of the vulva
159. Chromosonal translocations in benign tumors: The HMG1 proteins
160. HMGIC expression as a diagnostic marker for vulvar aggressive angiomyxoma
161. Mammary and extramammary Paget's disease
162. Anogenital 'sweat' glands: Histology and pathology of a gland that may mimic mammary glands
163. Mammary like glands on the vulva and their disorders
164. Vulvar Paget's disease: A clinicopathologic and immunohistochemical study of 19 cases
165. Perianal Paget's disease - A histologic and immunohistochemical study of 11 cases with and without associated rectal adenocarcinoma
166. Prognostic factors in Paget's disease of the vulva: A study of 21 cases
167. Proliferative epidermal lesions associated with anogenital Paget's disease